Zimbabwe has rejected a significant American healthcare agreement worth 367 million US dollars (£272m) over five years over Washington's demand for sensitive biological samples.
The decision was revealed following a internal memorandum from December was leaked, revealing that President Emmerson Mnangagwa felt the agreement was "lopsided".
An official representative has since stated that the United States was requesting health data for scientific study and commercial purposes while was unwilling to guarantee the benefits from future vaccines.
"We will now turn to the difficult and regrettable process of winding down our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had furnished more than $1.9bn in health funding to Zimbabwe over the last two decades.
A medical body in Zimbabwe has urged more dialogue to secure a agreement acceptable to both sides so the nation's vital HIV treatment initiative can be sustained.
Broader Context
This rejection comes after a comparable situation in Kenya, where a court halted a similar health funding agreement after concerns were filed about the safety of citizens' medical information.
Since returning to the presidency recently, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
USAID had administered assistance for the American government, but Trump stated its expenditure was "wasteful" and his administration was seeking direct bilateral deals to boost transparency and responsibility.
According to reports, Sixteen African countries have to date signed similar agreements, constituting over $18.3bn in committed funds.
Specifics of the Declined Deal
The money for Zimbabwe was intended to funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this partnership might have yielded immense advantages for Zimbabwean communities, particularly the 1.2 million currently on HIV treatment through US-supported initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana maintained the arrangement was "unfair".
"Our nation was requested to provide its biological resources and data for a long time, without any equivalent guarantee of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that provided information," his statement read.
"In essence, our country would provide the basic resources for scientific discovery without any certainty that the final treatments would be available to our people if a future health crisis emerge."
National Interest and Global Health
He also pointed out that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one deals were upending frameworks previously set up via the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing scheme created to deal with future pandemics.
"This mechanism is designed to ensure that when a country contributes its data, the benefits – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the capability to develop them."
Zimbabwe's reservations over the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We encourage continued discussions with our US partners on how subsequent collaboration might be designed in a manner that honours the independence and interests of each country."
Health Experts Reaction
Medical experts said it acknowledged the government's concerns, but urged that talks need to persist since a large portion of the nation's HIV programmes depended on foreign aid.
"Where technical issues exist, such as those involving data governance or agreement terms, these can frequently be addressed via detailed discussion and mutually agreed protections," the group added.
This impasse emphasises the complex tensions between accepting crucial foreign assistance and protecting local interests in an ever more data-driven world.